![](images/null.gif) |
![](images/null.gif) |
![](images/null.gif) |
|
Analysis of Sustained Viral Response and Boceprevir Resistance Following Combination Treatment With Boceprevir Plus Peginterferon Alfa-2a/Ribavirin in HCV Genotype 1 Prior Relapsers And Nonresponders
|
|
|
Reported by Jules Levin
AASLD Nov 5-8 2011 SF
J Howe1, R Ogert1, R Barnard1, D Hazuda1, LD Pedicone1, CA Brass1, JK Albrecht1, and S Flamm2
1Merck, Sharp & Dohme Corp., Whitehouse Station, NJ; 2Northwestern Feinberg School of Medicine, Chicago, IL
![AASLD1.gif](../images/111411/111411-15/AASLD1.gif)
![AASLD2.gif](../images/111411/111411-15/AASLD2.gif)
![AASLD3.gif](../images/111411/111411-15/AASLD3.gif)
![AASLD4.gif](../images/111411/111411-15/AASLD4.gif)
![AASLD5.gif](../images/111411/111411-15/AASLD5.gif)
![AASLD6.gif](../images/111411/111411-15/AASLD6.gif)
![AASLD7.gif](../images/111411/111411-15/AASLD7.gif)
![AASLD8.gif](../images/111411/111411-15/AASLD8.gif)
![AASLD9.gif](../images/111411/111411-15/AASLD9.gif)
![AASLD10.gif](../images/111411/111411-15/AASLD10.gif)
![AASLD11.gif](../images/111411/111411-15/AASLD11.gif)
![AASLD12.gif](../images/111411/111411-15/AASLD12.gif)
![AASLD13.gif](../images/111411/111411-15/AASLD13.gif)
![AASLD14.gif](../images/111411/111411-15/AASLD14.gif)
|
|
|
![](images/null.gif) |
![](images/null.gif) |
|
|